Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bausch Health Companies Inc.BHC · Entity 4363 | Director | September 30, 2026 | October 03, 2026 |
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Director | June 18, 2025 | June 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bausch Health Companies Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, No Par ValueSEC Table I · non-derivative | Direct | 316,158 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 1,179 · Balance 316,158 F1: Reflects Restricted Share Units issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2026, each representing a contingent right to receive one common share, no par value, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Restricted Share Units issued in lieu of cash compensation in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarter ending September 30, 2026, each representing a contingent right to receive one common share, no par value, of the Issuer.
Damora Therapeutics, Inc.
Report date June 18, 2025 · Filed June 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.22 · Expires 2035-06-18 | Direct | 720 |
Reported balance
After 2025-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 720 · Balance 720 F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2025, the date of the Issuer's 2025 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2017 Filed Oct 3, 2017 21:45 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 2,180 | $14.33 | $31,239.40 |
DisclosureSEC source: 0001127602-17-029036 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,542 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:04 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, No Par Value | 1,806 | $17.30 | $31,243.80 |
DisclosureSEC source: 0001127602-17-023065 · form4.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,362 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| May 05, 2017 Filed May 5, 2017 21:16 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 25,406 | $0.00 | $0.00 |
DisclosureSEC source: 0000885590-17-000027 · primary_doc.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,556 F1 · shares: Regular annual Restricted Share Units (RSUs) equal to $250,000 granted to non-employee directors in office on the third trading day following the Annual Meeting of Shareholders based on the closing price of registrant common stock on the date prior to the grant. RSUs represent a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:09 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 2,460 | $11.03 | $27,133.80 |
DisclosureSEC source: 0000885590-17-000023 · primary_doc.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,150 F1 · shares: Represents Restricted Share Units (RSUs) representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| December 30, 2016 Filed Jan 5, 2017 00:59 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 1,721 | $14.52 | $24,988.92 |
DisclosureSEC source: 0001677300-17-000001 · primary_doc.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,690 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 20:59 UTC | Bausch Health Companies Inc. VRX · Entity 4363 | GrantCommon Stock, no par value | 1,018 | $24.55 | $24,991.90 |
DisclosureSEC source: 0001677300-16-000008 · primary_doc.xml · nonDerivative · entry 1 WECHSLER AMY B · CIK 0001677300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,969 F1 · shares: Represents Restricted Share Units ("RSUs") representing a contingent right to receive one share of common stock, no par value, of Valeant Pharmaceuticals International, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.